Subscribe to RSS
DOI: 10.1055/s-2002-33696
© Georg Thieme Verlag Stuttgart · New York
Die Variante der Creutzfeldt-Jakob-Krankheit (vCJK)
The Creutzfeldt-Jakob Disease Variant (VCJD) Epidemiology, Diagnostics and Prevention with Particular Reference to Minimising the Risk of Iatrogenic Transfer via Medical Products, especially Surgical Instruments - Final VCJD Task Force ReportPublication History
Publication Date:
28 August 2002 (online)
Abdruck aus dem Bundesgesundheitsblatt 4/2002; 45: 376-394; Springer-Verlag, Heidelberg (Epidemiologie, Erkennung, Diagnostik und Prävention unter besonderer Berücksichtigung der Risikominimierung einer iatrogenen Übertragung durch Medizinprodukte, insbesondere chirurgische Instrumente - Abschlussbericht der Task Force vCJK zu diesem Thema)
Literatur
-
1 Hörnlimann B, Riesner D, Kretzschmar H. Prionen und Prionkrankheiten. Walter de Gruyter, Berlin, New York 2001
- 2 Prusiner S B. Shattuck lecture - neurodegenerative diseases and prions. N Engl J Med. 2001; 344 1516-1526
- 3 Brown P, Preece J-P, Brandel T, Sato L, McShane L, Zerr I, Fletcher A, Will R G, Pocchiari M, Cashman N R, dÀignaux J H, Cervenakova L, Fradkin J, Schonberger L B, Collins S J. Iatrogenic Creutzfeldt-Jakob Disease at the millenium. Neurology. 2000; 55 1075-1081
- 4 Hill A F, Desbruslais M, Joiner S, Sidle K C, Gowland I, Collinge J, Doey L J, Lantos P. The same prion strain causes vCJD and BSE. Nature. 1997; 389 448-449
- 5 Bruce M E, Will R G, Ironside J W, McConnell I, Drummond D, Suttie A, McCardle L, Chree A, Hope J, Birkett C, Cousens S, Fraser H, Bostock C J. Transmission to mice indicate that new variant CJD is caused by the BSE agent. Nature. 1997; 389 498-501
- 6 Duffy P, Wolf J, Collins G, DeVoe A G, Streeten B, Cowen D. Possible person to person transmission of Creutzfeldt-Jakob Disease. N Engl J Med. 1974; 290 693
- 7 Adams D H, Edgar W M. Transmission of agent of Creutzfeldt-Jakob Disease. Br Med J . 1978; 1 987
- 8 Gibbs C J, Asher D M, Kobrine A, Amyx H L, Sulima M P, Gajdusek D C. Transmission of Creutzfeldt-Jakob disease to a chimpanzee by electrodes contaminated during neurosurgery. J Neurol Neurosurg Psychiatry. 1994; 57 757-758
- 9 Heckmann J G, Lang C J, Petruch F, Druschky A, Erb C, Brown P, Neudorfer B. Transmission of CJD via corneal transplant. J Neurol Neurosurg Psychiatry. 1997; 63 388-390
- 10 Will R G, Ironside J W, Zeidler M, Cousens S N, Estibeiro K, Alperovitch A, Poser S, Pocchiari M, Hofman A, Smith P G. A new variant of Creutzfeldt-Jacob disease in the UK. Lancet. 1996; 347 921-925
- 11 Brown P, Will R G, Bradley R, Asher D M, Detwiler L. Bovine spongiform encephalopathy and variant Creutzfeldt-Jakob Disease: background, evolution and current concerns. Emerg Inf Dis. 2001; 7 No 1 6-16
- 12 Lasmézas C I, Fournier J G, Nouvel V, Boe H, Marce D, Lamoury F, Kopp N, Hauw J J, Ironside J, Bruce M, Dormont D, Deslys J P. Adaptation of the bovine spongiform encephalopathy agent to primates and comparison with Creutzfeldt-Jakob disease: Implications for human health. Proc Natl Acad Sci USA. 2001; 98 4142-4147
- 13 Hilton D A, Fathers E, Edwards P, Ironside J W, Zajicek J. Prion immunoreactivity in appendix before clinical onset of variant CJD. Lancet. 1998; 352 703-704
- 14 Hill A F, Butterworth R J, Joiner S, Jackson G, Rossor M N, Thomas D J, Frosh A, Tolley N, Bell J E, Spencer M, King A, Al-Sarraj S, Ironside J W, Lantos P L, Collinge. Investigation of variant Creutzfeldt-Jakob disease and other human prion diseases with tonsil biopsy samples. Lancet. 1999; 353 183-189
- 15 Bruce M E, McConnell I, Will R G, Ironside J W. Detection of variant CJD infectivity in extraneural tissues. Lancet. 2001; 358 208-209
- 16 Ironside J W, Hilton D A, Ghani A, Johnston N J, Conyers L, McCardle L M, Best D. Retrospective study on prion-protein accumulation in tonsil and appendix tissues. Lancet. 2000; 355 1693-1694
- 17 Wadsworth J DF, Joiner S, Hill A F, Campbell T A, Desbruslais M, Luthert P J, Collinge J. Tissue distribution of protease resistant prion protein in variant Creutzfeldt-Jacob disease using a highly sensitive immunoblotting assay. Lancet. 2001; 358 171-180
- 18 Schreuder BEC Geertsma R E, van Keulen L J, van Asten J A, Enthoven P, Oberthur R C, de Koeijer A A, Osterhaus A D. Studies on the efficacy of hyperbaric rendering procedures in inactivating bovine spongiform encephalopathy (BSE) and scrapie agents. Vet. Rec1998; 142 474-480
- 19 Rutala W A, Weber D J. Creutzfeldt-Jakob Disease. Recommendations for Disinfection and Sterilization. Clin Infect Dis. 2001; 32 1348-1356
- 20 Taylor D M. Inactivation of prions by physical and chemical means. J Hosp Inf. 1999; 43 (Supplement) 69-76
- 21 Taylor D M. Inactivation of transmissible degenerative encephalopathy agents: a review. Vet J. 2000; 159 10-17
-
22 Block S. Disinfection, Sterilization, and Preservation. 5th Edition. Lippincolt Williams u. Wilkins 2001
-
23 Risk assessment for Transmission of variant CJD via surgical instruments: A modelling approach and numerical scenarios. Economics and Operational Research Division Department of Health, London December 2000. http://www.doh.gov.uk/cjd/riskassessmentsi.htm
- 24 Laurenson I F, Whyte A S, Fox C, Babb J R. Contaminated surgical instruments and variant Creutzfeldt-Jakob disease. Lancet. 1999; 354 1823
- 25 Taylor D M, Fraser J R. Letters to the Editor/The potential risk of transmitting vCJD through surgery. J Hosp Inf. 2000; 44 318-319
- 26 Axon A, Beilenhoff U, Bramble M G, Ghosh S, Kruse A, McDonnell G E, Neumann C, Rey J -F, Spencer K. Variant Creutzfeldt-Jakob Disease (vCJD) and gastrointestinal endoscopy. Endoscopy. 2001; 33 1070-1080
- 27 Shmakow A N, Gosh S. Prion proteins and the gut: une liaison dangereuse?. Gut. 2001; 48 443-447
- 28 Kretzschmar H A. BSE und die neue Variante der Creutzfeldt-Jakob-Krankheit. Dt Ärzteblatt. 2001; 98 A 40 2576-2583
- 29 Manuedilis E E, Angelo J N, Gorgacz E J, Kim J H, Manuelidis L. Experimental CJD transmitted via the eye with infected cornea. N Engl J Med. 1977; 1334-1337
- 30 Carp R I. Transmission of scrapie by the oral route: Effect of gingival scarification. Lancet. 1982; 70-171
- 31 Brown P, Gibbs J rCJ, Rodger-Johnson P, Asher D M, Sulima M P, Bacote A, Goldfard L G, Gajdusek D C. Human spongiform encephalopathy: The National Institutes of Health Series of 300 cases of experimentally transmitted disease. Ann Neurology. 1994; 35 513-529
- 32 Fraser J R. Infectivity in extraneural tissues following intraocular scrapie infection. J Gen Virol. 1996; 77 2663-2668
- 33 Ingrosso L, Pisani F, Pocchiari M. Transmission of the 263K scrapie agent by the dental route. J Gen Virol. 1999; 80 3043-3047
- 34 Antloga K, Meszaros J, Malchesky P S, McDonnel G E. Prion Disease and Medical Devices. ASAIO Journal. 2000; 46 69-72
-
35 Schulz-Schaeffer W J, Beekes W, Kretzschmar H. Die Pathophysiologie von Prionkrankheiten nach peripherer Übertragung. In: Hörnlimann B, Riesner D, Kretzschmar H (Hrsg). Prionen und Prionkrankheiten. De Gruyter, Berlin 2001; 231-235
- 36 Sautereau D, Palazzo L. Pinces à biopsie à usage unique en endoscopie digestive: sage décision ou caricature du principe de précautation?. Gastroenterol Clin Biol. 2001; 25 653-655
- 37 Verjat D, Prognon P, Darbord J C. Fluorescence-assay on traces of protein on re-usable medical devices: cleaning efficiency. Int J Pharm. 1999; 179 267-271
- 38 Brown P, Rohwer R G, Green E M, Gajdusek D C. Effect of chemicals, heat, and histopathologic processing on high-infectivity hamster-adapted scrapie virus. J Infect Dis. 1982; 145 683-687
- 39 Brown P, Rohwer R G, Gajdusek D C. Newer data on the inactivation of scrapie virus or Creutzfeldt-Jakob disease virus in brain tissue. J Infect Dis. 1986; 153 1145-1148
- 40 Rohwer R G. Virus-like sensitivity of scrapie agent to heat inactivation. Science. 1984; 223 600-602
2 Schreiben des RKI vom 26. 2. 2001 und 10. 12. 2001
3 Schreiben des BfArm vom 30. 4. 2001
4 Unter Dekontamination im Sinne dieser Ausarbeitung wird ein Verfahren zur Abreicherung/Reduktion von organischen Verunreinigungen und gleichzeitiger oder aufeinanderfolgender Inaktivierung von Infektionserregern im Rahmen einer standardisierten Reinigung/Desinfektion von Medizinprodukten, bevorzugt in Reinigungs-Desinfektionsanlagen, verstanden. Maschinelle Verfahren erlauben die quantitative Analyse und Validierung des Prozesses und die Ermittlung eines reproduzierbaren .Dekontaminationsfaktors. (log Abreicherung).
5 Am ehesten lassen Reinigungsmittel auf der Basis von NaOH oder KOH unter Einbeziehung von Tensiden bei einer Einwirkzeit von 10 Minuten die gewünschte Wirkung erwarten; eine destablisierende Wirkung auf PrPsc sollte in geeigneten Prüfungen nachgewiesen sein; die Materialverträglichkeit kann durch geeignete Zusätze erhöht werden.
Prof. Dr. med. H.-J. Schulz
Direktor der Klinik für Innere Medizin
Krankenhaus Lichtenberg
Fanninger Str. 32
10365 Berlin
Email: schulz@khl-berlin.de